Review highlights the molecular diversity and clinical features of triple-negative breast cancer, indicating the need for targeted therapeutic approaches.
Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer. This review focuses on its origin, molecular and clinical characteristics, and treatment.
No takes yet. Share an insight, caveat, or question.
Foulkes et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: